Literature DB >> 2145325

Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal.

C K Job1, L Yoder, R R Jacobson, R C Hastings.   

Abstract

Skin biopsy specimens from two lepromatous leprosy patients with dark brown pigmentation who were receiving long-term clofazimine therapy were studied. Ceroid-lipofuscin pigment was demonstrated inside macrophages that contained numerous phagolysosomes. These contained lipids and clofazimine that appeared as electron-lucent vacuoles and a lipofuscin pigment that was electron dense, granular, and lamellated. Although the presence of the drug in tissues contributed to the skin pigmentation, the main cause was a drug-induced, reversible ceroid lipofuscinosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145325     DOI: 10.1016/0190-9622(90)70204-u

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  In Vitro Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against Mycobacterium tuberculosis.

Authors:  Lloyd Tanner; Joanna C Evans; Ronnett Seldon; Audrey Jordaan; Digby F Warner; Richard K Haynes; Christopher J Parkinson; Lubbe Wiesner
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Authors:  Nicole C Ammerman; Rosemary V Swanson; Elaine M Bautista; Deepak V Almeida; Vikram Saini; Till F Omansen; Haidan Guo; Yong Seok Chang; Si-Yang Li; Asa Tapley; Rokeya Tasneen; Sandeep Tyagi; Fabrice Betoudji; Chivonne Moodley; Bongani Ngcobo; Logan Pillay; Linda A Bester; Sanil D Singh; Richard E Chaisson; Eric Nuermberger; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.

Authors:  Yu Lu; Meiqin Zheng; Bin Wang; Lei Fu; Weijie Zhao; Peng Li; Jian Xu; Hui Zhu; Haixia Jin; Dali Yin; Haihong Huang; Anna M Upton; Zhenkun Ma
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

4.  Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis.

Authors:  Benoit Lechartier; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

5.  In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis.

Authors:  Jian Xu; Bin Wang; Lei Fu; Hui Zhu; Shaochen Guo; Haihong Huang; Dali Yin; Ye Zhang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  Rising to the challenge: new therapies for tuberculosis.

Authors:  Emily B Wong; Keira A Cohen; William R Bishai
Journal:  Trends Microbiol       Date:  2013-06-11       Impact factor: 17.079

Review 7.  Extensively Drug-Resistant Tuberculosis: Report and Literature Review on Two Cases Requiring Prolonged Treatment.

Authors:  Martha Matos-Tocasca; Gabriel De la Cruz-Ku; Erick Auccacusi; Diego Fernandez-Salas; Tatiana García-Ahuanari; Bryan Valcarcel-Valdivia
Journal:  Am J Case Rep       Date:  2016-11-03

8.  Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis.

Authors:  David W Dowdy; Alice A Zwerling; Andrea Stennett; Alexandra Searle; Vadim Dukhanin; Holly A Taylor; Maria W Merritt
Journal:  MDM Policy Pract       Date:  2020-04-26

9.  Leprosy stigma & the relevance of emergent therapeutic options.

Authors:  Kabir Sardana; Ananta Khurana
Journal:  Indian J Med Res       Date:  2020-01       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.